


4. (Amended) A compound according to claim 1 in which the ring A is thiophene.

A¹ 5. (Amended) A compound according to claim 1 in which R¹ represents optionally substituted phenyl.

6. (Amended) A compound according to claim 1 in which R² represents H or methyl.

9. (Amended) A process for the preparation of a compound of formula (I), according to claim 1, which comprises:

(a) reaction of a compound of formula (II):




wherein A, R¹ and R² are as defined in Claim 1 with an isocyanate (X = O) or an isothiocyanate (X = S); or

(b) reaction of compound of formula (III) with a compound of formula (IV)

R¹-Metal


(III)



(IV)

wherein A, X, R¹ and R² are as defined in Claim 1 and LG represents a leaving group; or

(c) reaction of compound of formula (V) with a compound of formula (VI)



wherein A, X, R^1 and R^2 are as defined in Claim 1 and LG represents a leaving group;
and where necessary converting the resultant compound of formula (I), or another salt thereof, into a pharmaceutically acceptable salt thereof; or converting the resultant compound of formula (I) into a further compound of formula (I); and where desired converting the resultant compound of formula (I) into an optical isomer thereof.

A2

10. (Amended) A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1, in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

A3

12. (Amended) A compound of formula (I), or a pharmaceutically-acceptable salt or solvate thereof, as claimed in claim 1 for use in therapy.

20. (Amended) A method of treating an IKK2 mediated disease which comprises administering to a patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1.

A4

21. (Amended) A method of treating an inflammatory disease in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1.--